Subject Index to Volume 144

SUBJECT INDEX TO VOLUME 144 A ABT 267, for hepatitis C, 144:482– ce ABT-333, for hepatitis C, 144:482– ce ABT-450/r, for hepatitis C, 144:482– ce Acetylcholine receptor agonist, ␣7 nicotinic, for gastrointestinal inflammation, 144:36 –rev Achalasia, treatment outcomes in, manometric subtype and, 144: 664 – cov, 144:681– e, 144:718 Acquired immune deficiency syndrome (AIDS). See HIV/ AIDS Adenomas colorectal characteristics of, associated with recurrent neoplasia, 144:1410 and genetic risk of colorectal cancer, 144:53 screening for, 144:664 – cov, 144: 684 – e, 144:743 surveillance, 144:1410 hepatocellular. See Hepatocellular adenoma intestinal initiation and growth, mesenchymal regulation of, 144:873– e, 144: 1001 regulation by Foxf2, 144:873– e, 144: 1001 metachronous, 144:1410 Adipocytes, metabolism, central melanin-concentrating hormone and, 144:475– cov, 144:501– e, 144:636 Adolescents, Concise Pediatric and Adolescent Hepatology, 144: 465–pmr AGA. See American Gastroenterological Association AIDS. See HIV/AIDS AIH. See Autoimmune hepatitis AIP. See Autoimmune pancreatitis Akt, in hepatic tumorigenesis (mice), 144:1055 Alcohol and pancreatic immune response, 144:1292

KEY TO ABBREVIATIONS aga—American Gastroenterological Association c—Correspondence cc—Comment From the Editors ccig—Clinical Challenges and Images in GI ctc—Covering the Cover e—Editorials eccig—Electronic Clinical Challenges and Images in GI gn—Gastroenterology News iat—Imaging and Advanced Technology

and pancreatitis, 144:1252, 144:1292 ALDH1, in pancreatic cancer stem cells, 144:1241 Alpha-amylase/trypsin inhibitor, in wheat, and intestinal inflammation, 144:1561–ss Alternative and complementary medicine, for inflammatory bowel disease, 144:36 –rev American Gastroenterological Association American Gastroenterological Association medical position statement on constipation, 144:211 American Gastroenterological Association technical review on constipation, 144:218 –aga Our new president—Anil K. Rustgi, 144:1129 Presentation of the Julius M. Friedenwald Medal to Chung Owyang, MD, 144:1554 Animal models of complex cholestatic disorders, 144: 1357–rev of intestinal neoplasia, 144:705–rev of pancreatic cancer, 144:1230 relevance to human disease, 144:1094 of pancreatitis, 144:1180 relevance to human disease, 144:1094 Anorectal manometry in constipation, 144:218 –aga high-resolution, in functional defecatory disorders, 144:263– e, 144:314 ␣1-Antichymotrypsin, antitumoral role in liver (mice), 144:818 Anticoagulation, in cirrhosis with portal vein thrombosis, 144: 848 –ss Anti-DLL4, and therapy targeted against pancreatic cancer stem cells, 144:1241 Antiplatelet therapy, and prevention of hepatocellular carcinoma in hepatitis B, 144: 1140 –ss

im—In Memoriam metc—Mentoring, Education, and Training Corner mrp—Mini-Reviews and Perspectives ms—Meeting Summary pmr—Print and Media Reviews rev—Reviews in Basic and Clinical Gastroenterology and Hepatology ss—Selected Summaries tmig—This Month in Gastroenterology

Antiretroviral therapy, combination, and HIV progression and mortality in HIV/HCV co-infection, 144:751 Aortic arch, double, 144:856 – ccig Apelin, regulation and role of, in intestine (mice), 144:771 Apoptosis butyric acid–induced, in colon cancer, 144:1576(correction) caspases and, 144:283–rev DNA damage–induced, 144:283–rev epithelial, and gut permeability and inflammation, 144:283–rev intrinsic pathway, 144:283–rev AR-R17779, and postoperative ileus (mice), 144:36 –rev Arteriovenous fistula, from subclavian and coronary arteries, 144:253– ccig Arteriovenous malformation, polypoid colonic, 144:1578 – ccig Aspirin, peptic ulcer bleeding related to, Helicobacter pylori and, 144:528 Asunaprevir, for hepatitis C, 144: 482– ce Autoimmune disease, and pancreatitis, 144:1252 Autoimmune hepatitis, Autoimmune Hepatitis: A Guide for Practicing Clinicians, 144:54 Autoimmune pancreatitis, 144:1163 clinical advances in, historical perspective on, 144:1249 epidemiology, 144:1252 management, 144:1272 models, 144:1180 relapsing, treatment of, 144:1144 –ss Autophagy defects, and inflammation, 144:1199 and exocrine pancreatic disorders, 144: 1199 obesity and, 144:1199 in pancreatitis, 144:1199 process of, 144:1199 B Bacteria. See Microbiota Bariatric surgery, ghrelin and (mice), 144:50 Barrett’s esophagus adult stem cells in, 144:761 cause-specific mortality in, 144:1375 dysplasia in, high-grade, risk of lymph node metastases in, 144:242–ss dysregulation of noncong RNAs in, 144: 956 esophageal cancer in, mortality from, 144:1375 genomics, 144:667– ce

e42

SUBJECT INDEX

mucosal cancer in, risk of lymph node metastases in, 144:242–ss pathogenesis of, 144:667– ce screening for, health benefits and cost effectiveness of, 144:62 BI 207127, for hepatitis C, 144: 482– ce Bile acids conjugation, genetic defects in, and fatsoluble vitamin deficiency, 144: 859 – cov, 144:870 – e, 144:945 Hepatobiliary Transport in Health and Disease, 144:855–pmr as modulators of gut microbiota, and IBD, 144:844 –ss prokinetic actions, TGR5 receptor and (mice), 144:145 Bile acid transporter inhibitor, for constipation, 144:218 –aga Bile duct stones intraductal lithotripsy for, 144:276 –iat removal, endoscopic sphincterotomy with balloon dilatation vs endoscopic sphincterotomy alone for, 144: 341 Bile duct tumors, intraductal ablation therapy for, 144:276 –iat Biliary atresia, susceptibility gene (human, zebrafish), 144: 878 – e, 144:1107 Biliary drainage, direct, cholangioscopy-guided, 144:276 –iat Biodesign in gastroenterology, 144:258 process for, 144:258 training in, 144:258 Biomarkers. See Epigenetics Biopsy, Biopsy Interpretation of the Gastrointestinal Tract Mucosa, Volume 2: Neoplastic, 2nd Edition, 144:1147–pmr Bleeding, upper gastrointestinal adjusted odds ratios for, 144:1327– cov, 144:1384 gastrocardiac fistula and, 144:251– ccig risk of, comorbidities and, 144:1327– cov, 144:1384 BMPR1A, mutations, and colorectal polyps, 144:1402 Body fat. See Obesity Bone mineral density, proton pump inhibitors and, 144: 650 –ss Brain, melanin-concentrating hormone in, and liver and adipose metabolism, 144:475– cov, 144: 501– e, 144:636 Brain-gut axis in inflammatory bowel disease, 144:36 – rev

GASTROENTEROLOGY Vol. 144, No. 7

modulation by fermented milk product with probiotic, 144:1394 C Calcium-sensing receptor, CASR, mutations, and pancreatitis, 144:1292 Cancer. See also Tumorigenesis Biopsy Interpretation of the Gastrointestinal Tract Mucosa, Volume 2: Neoplastic, 2nd Edition, 144:1147–pmr colon. See Colorectal cancer colorectal. See Colorectal cancer gastric. See Gastric cancer hepatic. See Hepatocellular carcinoma pancreatic. See Pancreatic cancer rectal. See Colorectal cancer; Rectal cancer Carbohydrates, absorption, intestinal glucose–apelin cycle and (mice), 144:771 Carbon monoxide, heme oxygenase1– derived, and intestinal homeostasis (mice, zebrafish), 144:789 Carcinogens, and rodent models of colon cancer, 144:705–rev Carcinosarcoma, esophageal, 144: 251– ccig Caspases and intestinal inflammation, 144:283–rev in pathogenesis of IBD, 144:283–rev and receptor-interacting protein kinases in necroptosis, 144:283–rev regulation of cell death in intestine, 144: 283–rev ␤-Catenin, in colon cancer cells, inhibition by SPDEF (mice), 144: 1012 Cathepsin E, in pancreatic imaging, 144:1262 CD. See Crohn’s disease CD24, in pancreatic cancer stem cells, 144:1241 CD44, in pancreatic cancer stem cells, 144:1241 CD133, in pancreatic cancer stem cells, 144:1241 Celiac.com, patient-oriented Internet content from, 144:246 –pmr Celiac disease and lowered prevalences of type 2 diabetes and metabolic syndrome, 144: 912 and pancreatitis, 144:1252 On patient-oriented Internet content on celiac sprue found on websites of Celiac Sprue Association, eMedicineHealth, MedicineNet, Celiac.com, WebMD, Right Diagnosis, and Celiac Disease Foundation, 144:246 –pmr

Celiac.org, patient-oriented Internet content from, 144:246 –pmr Celiac Sprue Association, patientoriented Internet content from, 144:246 –pmr Cell death. See Apoptosis CFTR. See Cystic fibrosis transmembrane conductance regulator Cholangiocarcinoma genomic and genetic features, and response to therapy, 144:665– cov, 144:687– e, 144:829 intrahepatic classification of, 144:665– cov, 144: 687– e, 144:829 genomics, 144:665– cov, 144:687– e, 144:829 Cholangioscopy advances in (future directions for), 144: 276 –iat diagnostic procedures, 144:276 –iat direct, 144:270, 144:276 –iat image-enhanced, 144:276 –iat peroral, 144:276 –iat therapeutic procedures, 144:276 –iat Cholangitis IgG4-related, Th2 cytokines in, and disruption of biliary epithelial cll barrier, 144:1116 and pancreatitis, associated with juxtapapillary diverticulum, 144:468 – ccig Cholecystitis, acute gangrenous, 144: 658 – ccig Cholestasis genetics of, 144:1357–rev Hepatobiliary Transport in Health and Disease, 144:855–pmr Cholestatic disorders, complex, genetics of, 144:1357–rev Chromoendoscopy, and detection of nonpolypoid neoplasms in inflammatory bowel disease, 144:1349 –v Chromosome region maintenance 1 (CRM-1), inhibitors, in pancreatic cancer treatment (mice), 144:257– cov, 144:447 Chymotrypsin, CTRC, mutations, and pancreatitis, 144:1292 Cigarette smoking. See Smoking Cirrhosis compensated, portal hypertension in, identification of, 144:2– cov, 144: 19 – e, 144:102, 144:1150 – c, 144:1151– c and esophageal varices, identification by measurement of spleen stiffness, 144:2– cov, 144:19 – e, 144:92, 144:1151– c, 144:1152– c

June 2013

HCV-related portal hypertension in, evaluation by measurement of spleen stiffness, 144:1152– c prognostic gene expression signature for, 144:876 – e, 144:1024 treatment of, 144:482– ce liver stiffness measurements in, 144: 19 – e organ failure and risk of death in, 144: 1337– e, 144:1426 and portal vein thrombosis, anticoagulation for, 144:848 –ss spleen stiffness measurements in, 144: 19 – e Claudin-2 (CLDN2 locus), and alcoholic pancreatitis, 144:1292 Clinical Challenges and Images in GI Cramping pain and eosinophilic ascites: What is the diagnosis?, 144:1353 A cutaneous marker of hepatitis C virus, 144:275 Double vision, 144:508 Dysphagia due to a “freak of nature,” 144:273 Dysphagia in a patient with recurrent small-cell lung cancer, 144:34 A man presenting with severe postprandial epigastric pain, jaundice, and pyrexia: More than the usual suspects?, 144:274 A naturopathic cause of portal venous gas embolism, 144:509 A rare but unique tumor in the esophagus, 144:695 A rare cause of an ileocecal fistula in an AIDS patient, 144:697 A rare pancreatic tumor in a 52-year-old Chinese woman, 144:511 A rash decision?, 144:884 Severe abdominal pain 2 days after endoscopic treatment, 144:1356 “Stalk”ing the etiology of rectal bleeding, 144:1355 Tense ascites in a postpartum woman, 144:272 An uncommon cause of focal liver lesion, 144:510 An uncommon malignancy of the esophagus, 144:32 An unusual case of chronic diarrhea, 144: 696 An unusual case of epigastric pain: Two causes for one disease, 144:885 Unusual cause of abdominal pain, 144: 886 An unusual cause of dysphagia, 144:694 An unusual cause of elevated liver enzymes in a diabetic patient, 144: 1354

SUBJECT INDEX

An unusual cause of upper gastrointestinal bleeding, 144:33 Vascular lesions in an adult mimicking esophageal varix, 144:35 A woman with pruritus ani, 144:887 c-Met, and pancreatic cancer stem cells, 144:1241 CNI-1493, for gastrointestinal inflammation, 144:36 –rev Coffee, and liver disease, 144:670 – ce Colectomy, subtotal, for slow transit constipation, 144:218 –aga Colitis. See also Ulcerative colitis alleviation by molecular/chemical chaperones (mice), 144:989 and colon cancer-inducing activity of microbiota, 144:461–ss depression and, 144:36 –rev early life events and, 144:36 –rev experimental models, heme oxygenase-1 and (mice, zebrafish), 144:789 microscopic, lansoprazole-induced, 144: 857– ccig phelebosclerotic, 144:1159 – ccig T-cell–mediated, Foxp3 expression by Tregs in, IFN and (mice), 144: 1157(correction) Colon adenomas. See Adenomas barostat testing, in constipation, 144: 218 –aga manometry, in constipation, 144:218 – aga polypoid arteriovenous malformation of, 144:1578 – ccig Colon cancer. See Colorectal cancer Colonic transit, in constipation, 144: 218 –aga Colonoscopy anesthesia assistance during, and outcomes, 144:298 features on, associated with recurrent neoplasia, 144:1410 polypectomy in, technique for, 144: 16 – e, 144:74 retroflexion in, 144:882–v Colorectal adenomas. See Adenomas Colorectal cancer ␤-catenin signaling in, inhibition by SPDEF (mice), 144:1012 butyric acid–induced apoptosis in, 144: 1576(correction) development of, IL-8 and (mice), 144: 155 familial occurrence of, 144:474 – cov, 144:492– e, 144:544 genetic risk for, adenoma susceptibility and, 144:53

e43

genetic susceptibility loci for, 144:665– cov, 144:799 HMGA1/miR-137/FMNL2 axis in (mice), 144:624 laparoscopic surgery for, duration of ileus after, electroacupuncture and, 144:255– cov, 144:307 microbiota and inflammation in, 144: 461–ss microsatellite instability and, 144: 868 – e, 144:926 modeling, in rodents, 144:705–rev risk, among siblings of colorectal cancer patients, 144:474 – cov, 144: 492– e, 144:544 screening, 144:664 – cov, 144:684 – e, 144:743 family history of colon cancer and, 144:474 – cov, 144:492– e, 144: 544 immunochemical fecal occult blood tests for, comparisons of, 144:918 submucosal invasive, long-term outcomes with, 144:551 tumor-suppressor functions of SPDEF in, 144:1012 Commentaries Barrett’s esophagus: Evolutionary insights from genomics, 144:667 Bibliometrics of the top 100 clinical articles in digestive disease, 144: 673 CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: Overview and take-home messages, 144:478 How to value technological innovation: A proposal for determining relative clinical value, 144:5 Is it time to write a prescription for coffee? Coffee and liver disease, 144: 670 Is the HCV pipeline heading in the right direction?, 144:482 Update in Print and Media Reviews: Not your father’s book review section, 144:486 Complete Adenoma Resection (CARE) study, results, 144: 16 – e, 144:74 Confocal endomicroscopy Atlas of Gastrointestinal Endomicroscopy, 144:854 –pmr of mast cell and neural axis of gut, 144: 698 –iat Constipation AGA medical position statement on, 144:211–aga AGA technical review on, 144:218 –aga chronic classification of, 144:218 –aga

e44

SUBJECT INDEX

definition of, 144:218 –aga clinical evaluation, 144:211–aga clinical subgroups of, 144:211–aga in defecatory disorders, 144:211–aga, 144:218 –aga definition of, 144:211–aga diagnostic tests for, 144:211–aga economic impact of, 144:218 –aga medical management of, 144:211–aga, 144:218 –aga medications associated with, 144:218 – aga normal transit, 144:211–aga, 144:218 – aga pathophysiology of, 144:218 –aga pharmacological agents for, 144:218 –aga comparison of, 144:218 –aga prevalence of, 144:218 –aga and quality of life, 144:218 –aga risk factors for, 144:218 –aga slow transit, 144:211–aga, 144:218 –aga surgical treatment of, 144:218 –aga surgical treatment of, 144:211–aga, 144: 218 –aga Correspondence It is premature to conclude pancreatic sphincterotomy is not beneficial in idiopathic pancreatitis, 144: 1570 Liver stiffness, platelets, and spleen size is reliable in nondecompensated cirrhotic patients, 144:1150 Noninvasive predictors of portal hypertension, 144:1150 Statins and cancer in gastroenterology: New insight?, 144:1572 The underestimated role of opiates in spincter of Oddi dysfunction, 144:1571 What is the role of noninvasive treatment for infected pancreatic necrosis: Still an unanswered question, 144:1574 Corticotropin-releasing factor (CRF), and gastrointestinal inflammation, 144:36 –rev Costs and cost analysis and anesthesia assistance during colonoscopy, 144:298 of Barrett’s esophagus screening, 144:62 of birth cohort screening for hepatitis C antibody in US primary care settings, 144:457–ss of endoscopic sphincterotomy with balloon dilatation vs endoscopic sphincterotomy alone for removal bile duct stones, 144:341 of new technology, 144:5– ce Covering the Cover Achalasia types and treatment success, 144:664

GASTROENTEROLOGY Vol. 144, No. 7

Age and gender influences on the clinical phenotype of primary biliary cirrhosis, 144:474 Altered response to gluten in diarrheapredominant IBS, 144:859 Community practice experience with narrow band imaging-based biopsies, 144:1 Comorbidities and risk of upper gastrointestinal bleeding, 144:1327 Drug-induced liver injury population data from Iceland, 144:1328 Effects of melanocortin-4 receptors on glucose homeostasis after gastric bypass, 144:474 Electroacupuncture decreases postoperative ileus duration, 144:255 Genetics of fat-soluble vitamin deficiency, 144:859 Importance of natural killer cells in clearance of experimental hepatitis B virus, 144:256 Large-scale expression quantitative trait loci analysis of human ileum, 144:1328 Magnetic resonance colonography for neoplasia screening, 144:664 Melanin-concentrating hormone effects on liver and adipose metabolism, 144:475 Metabolomic profiling to assess hepatocellular carcinoma outcome risk, 144:860 New genetic susceptibility loci in colorectal tumors, 144:665 The nuclear factor -␬B pathway in experimental pancreatitis, 144:3 Reduction of liver cancer risk by statins: Meta-analysis, 144:255 Regulation of pancreas development and homeostasis by Hippo signaling, 144:1329 Replication models of hepatitis C virus genotypes 3a and 4, 144:1 Risk of neoplasms among asymptomatic siblings of patients with colorectal cancer, 144:474 Targeting of nuclear export shrinks pancreatic tumors in mice, 144:257 Two molecular phenotypes in intrahepatic cholangiocarcinoma, 144: 665 Utility of liver and spleen stiffness measurements, 144:2 A vaccine to prolong survival in experimental pancreatic cancer, 144: 861 Cowden syndrome, genetics of, 144: 1402 CRC. See Colorectal cancer

Crohn’s and Colitis Foundation of America, website information on IBD, 144:248 –pmr Crohn’s disease intestinal CD8⫹ T suppressor cell activity in, TGF-␤ signaling and, 144:601 necroptosis in, 144:283–rev pathogenesis, PTPN22 and IFN-␥–induced signaling in, 144:978 polygenic traits, 144:667– ce susceptibility loci for, in Japanese population, 144:781 ustekinumab for, 144:846 –ss CUR199691, and therapy targeted against pancreatic cancer stem cells, 144:1241 CXCR4, in pancreatic cancer stem cells, 144:1241 Cyclooxygenase 2 (Cox2), and genetic models of chronic pancreatitis in mice, 144:1080 Cyclosporine, for severe ulcerative colitis refractory to steroids, 144:1138 –ss Cystic fibrosis, and pancreatic disorders, 144:1292 Cystic fibrosis transmembrane conductance regulator and genetic models of chronic pancreatitis, 144:1080 and pancreatic disorders, 144:1292 Cytosponge, for Barrett’s esophagus screening, health benefits and cost effectiveness of, 144:62 D DAAs. See Direct-acting antiviral agents Daclatasvir, for hepatitis C, 144: 482– ce Defecatory disorders behavioral treatment of, 144:218 –aga constipation caused by, 144:211–aga, 144:218 –aga functional high-resolution anorectal manometry in, 144:263– e, 144:314 phenotypes of, 144:263– e, 144:314 management of, 144:218 –aga pathophysiology of, 144:218 –aga treatment of, 144:211–aga Defecography barium, in constipation, 144:218 –aga magnetic resonance, in constipation, 144: 218 –aga scintigraphic, in constipation, 144:218 – aga Dendritic cells, myeloid, human type 2 interferon-␭ production by, 144:414 recognition of hepatitis C virus, 144:414

June 2013

Diabetes mellitus and pancreatitis, 144:1252, 144:1282 response to bariatric surgery, 144:474 – cov, 144:497– e, 144:580 type 2, risk reduction, celiac disease and, 144:912 Diet interactions with microbiota and intestinal transit, in humanized mice, 144:967 and pancreatitis, 144:1252 Direct-acting antiviral agents. See also specific agent for hepatitis C, 144:482– ce Diverticulitis, heritability and familial aggregation of, 144:736 Diverticulosis, heritability and familial aggregation of, 144:736 Diverticulum duodenal, 144:468 – ccig juxtapapillary, 144:468 – ccig Drug-induced liver injury, Iceland data, 144:1328 – cov, 144: 1335– e, 144:1419 Drug-induced pancreatitis, acute, 144:1252, 144:1272 Duodenum, intramural hematoma after endoscopic hemostasis, 144:1579 – ccig Dysphagia, double aortic arch and, 144:856 – ccig Dysphagia lusoria, 144:467– ccig E Editorials Bariatric surgery in the era of personalized medicine, 144:497 Can high-resolution anorectal manometry shed new light on defecatory disorders?, 144:263 The Cheesecake Factory: Lessons for expanding the menu for colorectal cancer screening, 144:684 Defining acute-on-chronic liver failure: Will East and West ever meet?, 144:1337 Drug-induced liver injury: Icelandic lessons, 144:1335 Familial colorectal cancer screening: So close, so far, 144:492 Fishing for biliary atresia susceptibility genes, 144:878 FoxD3 is a novel, epigenetically regulated tumor suppressor in gastric carcinogenesis, 144:22 Foxf2: A mesenchymal regulator of intestinal adenoma development, 144: 873 Genomic decoding of intrahepatic cholangiocarcinoma reveals therapeutic opportunities, 144:687

SUBJECT INDEX

Hepatitis C virus replicons volume 3 and 4, 144:13 Hippo signaling maintains the phenotype of pancreatic acinar cells, 144:1345 Linking genetic variation to phenotype: eQTL analysis of normal human ileum, 144:1339 Modern hepatomancy, 144:876 The mystery of mismatch repair deficiency: Lynch or Lynch-like?, 144:868 Not all PBC is the same!, 144:494 Nuclear factor-␬B in pancreatitis: Jackof-all-trades, but which one is more important?, 144:26 Preventing pancreatitis by protecting the mitochondrial permeability transition pore, 144:265 Targeting innate immunity: A new step in the development of combination therapy for chronic hepatitis B, 144:1342 Two paths diverge in the brain: Melanin-concentrating hormone controls hepatic and adipose metabolism, 144:501 Uncovering hidden information in achalasia using esophageal pressure topography, 144:681 When bile acids don’t get amidated, 144:870 When the spleen gets tough, the varices get going, 144:19 Why we should CARE about polypectomy technique, 144:16 Education and training. See also Mentoring, Education, and Training Corner in communication skills, 144:1330 direct trainee observation in, 144:1330 Essentials of Gastroenterology, 144:853–pmr procedural competency of gastroenterology trainees, 144:677 of US minorities, 144:863 Washington Manual® Subspecialty Consult Series in Gastroenterology, 3rd Edition, 144:466 –pmr E2F1/E2F2, deletion, and genetic models of chronic pancreatitis, 144:1080 Eicosanoids, production of, and monoacylglycerol lipase-modulated hepatic injury (mice), 144:808 Elastography, of pancreas, 144:1262 Electroacupuncture, and duration of postoperative ileus, 144:255– cov, 144:307 eMedicineHealth information on IBD, 144:248 –pmr

e45

patient-oriented Internet content from, 144:246 –pmr Endocannabinoids, and monoacylglycerol lipase-modulated hepatic injury (mice), 144:808 Endoscopic confocal microscopy, of gut neuronal elements, 144: 698 –iat Endoscopic microgrippers, for biologic tissue sampling, 144: 691–v Endoscopic retrograde cholangiopancreatography in acute idiopathic recurrent pancreatitis, 144:1570 – c, 144:1571– c for biliary pancreatitis, timing of, 144: 1272 historical perspective on, 144:1249 pancreatitis after, prevention, 144:1272 Endoscopic retrograde pancreatography (ERP), 144:1262 Endoscopic submucosal dissection, gastric, novel submucosal gel for, 144:505 Endoscopic ultrasound of pancreas, 144:1262 enhanced, 144:1262 historical perspective on, 144:1249 with solid tumors, 144:1262 of pancreatic cystic neoplasms, 144:1303 Endoscopy. See also Colonoscopy Atlas of Gastrointestinal Endomicroscopy, 144:854 –pmr for Barrett’s esophagus screening, health benefits and cost effectiveness of, 144:62 intramural duodenal hematoma after, 144:1579 – ccig procedural competency of gastroenterology trainees, 144:677 resection of sessile polyps in, 144:30 –v Self-Expanding Stents in Gastrointestinal Endoscopy, 144:245–pmr simulation in, 144:9 therapeutic, in idiopathic recurrent acute pancreatitis, 144:1570 – c, 144: 1571– c ENG, mutations, and colorectal polyps, 144:1402 Enhancer of zeste 2 homolog, silencing of miR-218 in pancreatic cancer, 144:1086 ENO1 DNA vaccine, for pancreatic ductal adenocarcinoma (mice), 144:861– cov, 144: 1098 Entecavir, for chronic hepatitis B, and accuracy of HCC risk scores, 144:933 Enteric neuronal networks, imaging of, 144:698 –iat

e46

SUBJECT INDEX

Enteritis, stress-induced CRH-mediated NLRP6 inflammasome inhibition and (mice), 144: 1478 Eosinophilic esophagitis, dietary management for, 144:1560 –ss Eosinophilic gastroenteritis, 144: 1577– ccig Epigenetics, of noncoding RNA in Barrett’s esophagus and esophageal adenocarcinoma, 144:956 Epithelial barrier function, biliary, disruption by Th2 cytokines, 144:1116 Epithelial cells, intestinal, homeostasis, negative feedback control of, 144:873– e, 144:1001 ERCP. See Endoscopic retrograde cholangiopancreatography ESA, in pancreatic cancer stem cells, 144:1241 Esophageal cancer adenocarcinoma, dysregulation of noncong RNAs in, 144:956 adult stem cells in, 144:761 in Barrett’s esophagus, mortality from, 144:1375 carcinosarcoma, 144:251– ccig melanoma, 144:856 – ccig optical imaging of periostin in (mice), 144:294 Esophageal dysplasia, adult stem cells in, 144:761 Esophageal manometry, in achalasia, 144:664 – cov, 144:681– e, 144:718 Esophageal pressure topography, in achalasia, 144:664 – cov, 144:681– e, 144:718 Esophageal varices in cirrhotic patients identification by measurement of spleen stiffness, 144:2– cov, 144: 19 – e, 144:92, 144:1151– c, 144: 1152– c prediction of, 144:2– cov, 144:19 – e, 144:102, 144:1150 – c, 144: 1151– c in HCV-related cirrhosis, evaluation by measurement of spleen stiffness, 144:1152– c Esophagus. See also Barrett’s esophagus adult stem cells in, 144:761 cancer. See Esophageal cancer The Esophagus, 5th Edition, 144:1148 – pmr Everolimus, for liver transplant recipients, 144:459 –ss

GASTROENTEROLOGY Vol. 144, No. 7

Expression quantitative trait loci (eQTL) analysis, of human ileum, 144:1328 – cov, 144: 1339 – e, 144:1488 F Faldaprevir, for hepatitis C, 144: 482– ce Fecal immunochemical test, for colorectal cancer screening, comparisons of, 144:918 Fiber, dietary, supplementation, for constipation, 144:218 –aga Fibroblasts, stromal, and pancreatic cancer, 144:1230 Fibrosis, hepatic coffee and, 144:670 – ce congenital, in autosomal recessive polycystic kidney disease, 144:112, 144:1155– c elastography-based assessment of, and prognosis, in primary biliary cirrhosis, 144:851–ss promotion by TGF-␤ signaling in hepatocytes of TAK1 knockout mice, 144:1042 Filariasis, and eosinophilic gastroenteritis, 144:467– ccig Fistula gastrocardiac, with active bleeding, 144: 251– ccig ileocecal, in HIV-infected (AIDS) patient, Histoplasma capsulatum infection and, 144:857– ccig Fluoroscopy, Practical Fluoroscopy of the GI and GU Tracts, 144: 656 –pmr Focal nodular hyperplasia diagnosis of, 144:888 –rev immunohistochemistry of, 144:888 –rev pathophysiology of, 144:888 –rev treatment of, 144:888 –rev Foregut duplication cyst, hepatic, 144:658 – ccig Formin-like 2, correlation with miR137 and HMGA1 in colorectal cancer (mice), 144:624 Forte, John Gaetano, 144:471 Foundation for Clinical Research in IBD, website information on IBD, 144:248 –pmr FOXD3 cascade, and gastric carcinogenesis, 144:22– e, 144:122 Fujiwara, Kenji, 144:661 G Galantamine, for gastrointestinal inflammation, 144:36 –rev Gallstone disease animal models of, 144:1357–rev genetics of, 144:1357–rev

non-HLA associations in, 144:1357–rev and pancreatitis, 144:1252 Gastric cancer, FoxD3 dysregulation by Helicobacter pylori and, 144:22– e, 144:122 Gastric hypersensitivity, functional dyspepsia-like, developmental origins of (rats), 144:570 Gastroenteritis, eosinophilic, 144: 467– ccig Gastroenterology Essentials of Gastroenterology, 144:853–pmr Washington Manual® Subspecialty Consult Series in Gastroenterology, 3rd Edition, 144:466 –pmr GASTROENTEROLOGY, Print and Digital Media Reviews, update on, 144:486 – ce Gastroenterology in Motion Biologic tissue sampling with untethered microgrippers, 144:691 The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease, 144:1349 Direct cholangioscopy: New horizons for complex intraductal treatments under direct high-resolution visualization, 144:270 Endoscopic resection of sessile colon polyps, 144:30 A novel submucosal gel permits simple and efficient gastric endoscopic submucosal dissection, 144:505 Rtroflexion in colonoscopy: Why? Where? When? How? What value?, 144:882 Gastrointestinal stromal (GIST)like tumors, in Patched1 mutant mice, 144:134 Gastroparesis, Gastroparesis: Pathophysiology, Presentation and Treatment, 144:1146 –pmr Gene expression host, regulation by gut microbiota, 144: 841–ss in human intestine, genotype and, 144: 1328 – cov, 144:1339 – e, 144: 1488 Genetics of complex cholestatic disorders, 144: 1357–rev of diverticular disease, 144:736 of pancreatitis, 144:1292 and rodent models of colon cancer, 144: 705–rev Genome-wide association study (GWAS) in complex cholestatic disorders, 144: 1357–rev

June 2013

and susceptibility loci for colorectal tumors, 144:665– cov, 144:799 and susceptibility loci for Crohn’s disease, in Japanese population, 144: 781 Genomics, of Barrett’s esophagus, 144:667– ce Genotype, and gene expression in human intestine, 144:1328 – cov, 144:1339 – e, 144:1488 Ghrelin, and weight-loss surgery (mice), 144:50 Glucose–apelin cycle, intestinal, and carbohydrate absorption (mice), 144:771 Gluten intolerance, in pregnant women, and fetal weight/birth weight, 144: 726 sensitivity and diarrhea-predominant irritable bowel syndrome, 144:859 – cov, 144:903 and lowered risk for type 2 diabetes and metabolic syndrome, 144: 912 Glycogenic hepatopathy, 144:1577– ccig Goblet cells, mucin production, IL-10 and, 144:357 GPC1, as biliary atresia susceptibility gene (human, zebrafish), 144: 878 – e, 144:1107 GS 5885, for hepatitis C, 144:482– ce GS-9620, suppression of hepatitis B virus in chronic infection (chimpanzee), 144:1342– e, 144:1508 GTS-21, and innate immune response, 144:36 –rev H Hamartomatous polyposis, genetics of, 144:1402 HBV. See Hepatitis B/Hepatitis B virus HCC. See Hepatocellular carcinoma HCV. See Hepatitis C/Hepatitis C virus Hedgehog Indian, and genetic models of chronic pancreatitis, 144:1080 Helicobacter pylori and aspirin-related ulcer bleeding, 144: 528 CD4⫹ T-cell response to, and gastric disease risk reduction, 144:591 eradication, first-line regimen for, 144: 652–ss first-line treatment of, 144:652–ss

SUBJECT INDEX

FoxD3 dysregulation by, and gastric carcinogenesis, 144:22– e, 144:122 Heme oxygenase-1, and intestinal inflammation (mice, zebrafish), 144:789 Hepatitis autoimmune. See Autoimmune hepatitis viral, coffee and, 144:670 – ce Hepatitis B/Hepatitis B virus chronic combination therapy for, 144:1342– e, 144:1508 entecavir treatment, and HCC risk score accuracy, 144:933 GS-9620 suppression of (chimpanzee), 144:1342– e, 144:1508 hepatocellular carcinoma development in, predictive scores for, 144:933 clearance, natural killer cells and (mice), 144:256 – cov, 144:392 hepatocellular carcinoma development in prediction of, 144:933 prevention by antiplatelet therapy (mice), 144:1140 –ss tertiary prevention of, 144:1142–ss Hepatitis C/Hepatitis C virus antibody, birth cohort screening for, in US primary care settings, 144: 457–ss cirrhosis caused by esophageal varices with, evaluation by measurement of spleen stiffness, 144:1152– c portal hypertension in, evaluation by measurement of spleen stiffness, 144:1152– c prognostic gene signature in, 144: 876 – e, 144:1024 treatment of, 144:482– ce genotype 1, differential interferon response in, 144:402 genotype 4, subgenomic replicons, 144: 1– cov, 144:13– e, 144:59 genotype 3a, replication in cultured cells, 144:1– cov, 144:13– e, 144:56 and HIV, co-infection effects on HIV progression and mortality, 144:751 treatment of, 144:482– ce interferon for, differential response to, 144:402 recognition by human type 2 myeloid dendritic cells, 144:414 replication, suppression, IFN␣ effector genes required for, 144:1337– e, 144:1426 screening for CDC and USPSTF 2012 recommendations for, 144:478 – ce recommendations for, 144:478 – ce

e47

sustained virologic response to therapy and dose selection, 144:1450 as end point for regulatory approval, 144:1450 treatment of access to care and, 144:482– ce advances in (future directions for), 144:482– ce disparities in, 144:482– ce Hepatocellular adenoma ␤-catenin–activated, 144:888 –rev diagnosis of, 144:888 –rev HNF1A-mutated, 144:888 –rev inflammatory, 144:888 –rev molecular classification of, 144:888 –rev pathogenesis of, 144:888 –rev prognosis for, 144:888 –rev treatment of, 144:888 –rev unclassified, 144:888 –rev Hepatocellular carcinoma angiogenesis in, 144:512–rev antitumor role of ␣1-antichymotrypsin in (mice), 144:818 autophagy and, 144:512–rev chemoprevention of, 144:512–rev in chronic hepatitis B entecavir treatment and risk score accuracy for, 144:933 prediction of, 144:933 development of, SPOCK1 and (mice), 144:179 fibroblasts and, 144:512–rev fibrosis and, 144:512–rev in hepatitis B prevention by antiplatelet therapy (mice), 144:1140 –ss tertiary prevention of, 144:1142–ss hypoxia and, 144:512–rev immune cells and, 144:512–rev inflammation and, 144:512–rev invasiveness, SPOCK1 and (mice), 144: 179 Jagged-1 upregulation in, YAP and, 144:1530 lipid biomarkers in, 144:860 – cov, 144: 1066 macrophages and, 144:512–rev metabolic profiling of, 144:860 – cov, 144:1066 metastases, SPOCK1 and (mice), 144: 179 microenvironment in, 144:512–rev animal models for study of, 144:512– rev molecular therapies for, 144:512–rev nontumor adjacent tissue in, prognostic significance of, 144:512–rev Nor-1 upregulation in, 144:1518 Notch signaling in, YAP and, 144:1530

e48

SUBJECT INDEX

outcomes with, gene expression and metabolic profiling analyses of factors affecting, 144:860 – cov, 144: 1066 oxidative stress and, 144:512–rev pathogenesis of, 144:512–rev progression, gene expression and metabolic profiling analyses of factors affecting, 144:860 – cov, 144: 1066 promotion by TGF-␤ signaling in hepatocytes of TAK1 knockout mice, 144:1042 risk modification, with statins, 144:255– cov, 144:323, 144:1572– c SPOCK1 in, 144:179 stem cells, 144:512–rev ICAM-1 expression by, 144:1031 stroma, as therapeutic target, 144:512– rev treatment of, 144:512–rev Hepatocytes glycogen deposition in, 144:1577– ccig metabolism, central melanin-concentrating hormone and, 144:475– cov, 144:501– e, 144:636 proliferation, Nor-1 and, 144:1518 Hepatotoxicity, drug-related, incidence, presentation, and outcomes with, 144:1328 – cov, 144:1335– e, 144:1419 Hernia, hiatal, polygenic traits, 144: 667– ce High-mobility group AT-hook, HMGA1, correlation with miR137 and FMNL2 in colorectal cancer (mice), 144:624 Hippo signaling, in pancreatic acinar cells, and differentiation and maintenance of phenotype (mice), 144:1329 – cov, 144:1345– e, 144:1543 Histoplasma capsulatum, gastrointestinal infection, 144:857– ccig HIV/AIDS gastrointestinal Histoplasma capsulatum infection in, 144:857– ccig and HCV co-infection effects on HIV progression and mortality, 144:751 treatment of, 144:482– ce Human cytokeratin 8, and genetic models of chronic pancreatitis, 144:1080 Human immunodeficiency virus (HIV). See HIV/AIDS 27-Hydroxycholesterol, effects on cholesterol accumulation and steatohepatitis (mice), 144:167

GASTROENTEROLOGY Vol. 144, No. 7

I IBD. See Inflammatory bowel disease IBS. See Irritable bowel syndrome IL. See Interleukin(s) Ileum, normal human, expression quantitative trait loci (eQTL) analysis, 144:1328 – cov, 144: 1339 – e, 144:1488 Ileus, postoperative, duration of, electroacupuncture and, 144:255– cov, 144:307 Imaging. See also Molecular imaging of acute pancreatitis, 144:1272 of chronic pancreatitis, 144:1282 of mast cell-nerve axis in gut, 144:698 –iat of pancreas, 144:1163, 144:1262 historical perspective on, 144:1249 of pancreatic cancer, 144:1262 of pancreatic cystic lesions, 144:1262 Practical Fluoroscopy of the GI and GU Tracts, 144:656 –pmr Imaging and Advanced Technology Functions and imaging of mast cell and neural axis of the gut, 144:698 Peroral cholangioscopy: Diagnostic and therapeutic applications, 144:276 Immune regulation and pancreatic ductal carcinoma, 144:1230 and pancreatitis, 144:1230, 144:1292 Immune response HCV-specific, antiviral efficacy of, ex vivo, 144:426 to Helicobacter pylori, and reduced risk of gastric disease, 144:591 innate, activation, in treatment of chronic hepatitis B (chimpanzee), 144:1342– e, 144:1508 Immune tolerance, innate, in differential response to interferon therapy for HCV, 144:402 Immunohistochemistry, of rodent models of colon cancer, 144: 705–rev Immunomodulators, for relapsing autoimmune pancreatitis, 144: 1144 –ss Immunotherapy, for pancreatic ductal adenocarcinoma (mice), 144:861– cov, 144:1098 Inflammation autophagy defects and, 144:1199 epithelial apoptosis and cell shedding in, 144:283–rev and exocrine pancreatic disorders, 144:1199 intestinal IL-8 and (mice), 144:155 loss of PTPN22 and, 144:978 prevention by heme oxygenase-1 (mice), 144:789

regulation by caspases, 144:283–rev stress-induced CRH-mediated NLRP6 inflammasome inhibition and (mice), 144:1478 Kras in, 144:1220 mucosal, TREM-2 in (mice), 144:346 obesity and, 144:1199 in pancreatic ductal carcinoma development, 144:1199 in pancreatitis, 144:1199 Inflammatory bowel disease. See also Crohn’s disease; Ulcerative colitis angiogenesis in, TLR/NLR-mediated, 144:613 and autoimmune pancreatitis, in animal models, 144:1180 brain-gut interactions in, 144:36 –rev dietary habits and microbiota in, 144: 844 –ss expression quantitative trait loci (eQTL) analysis and, 144:1328 – cov, 144:1339 – e, 144:1488 On inflammatory bowel disease found on websites WebMD, eMedicineHealth, MedicineNet, Crohn’s and Colitis Foundation of America, Foundation for Clinical Research in IBD, UpToDate, and Wikipedia, 144:248 – pmr mouse model, alleviation by molecular/ chemical chaperones, 144:989 nonpolypoid neoplasms in, detection and targeted biopsy of, 144:1349 –v and pancreatitis, 144:1252 pathogenesis, TREM-2 in, 144:346 psychological interventions in, 144:36 – rev Infliximab, for severe ulcerative colitis refractory to steroids, 144: 1138 –ss Inhibitor of NF-␬B kinase, and genetic models of chronic pancreatitis, 144:1080 In Memoriam John Gaetano Forte, 144:471 Kenji Fujiwara, 144:661 Insulin, sensitivity, in metabolic syndrome, microbiota transfer from lean donors and, 144: 250(correction) Intercellular cell adhesion molecule, ICAM-1, expression by hepatocellular carcinoma stem cells and circulating tumor cells, 144:1031 Interferon IFN-␣ antiviral response to, in hepatitis C, innate immune tolerance and, 144:402

June 2013

effector genes, antiviral function in hepatitis C, 144:1337– e, 144: 1426 IFN-␥ secretion by virus-specific CD8⫹ T cells, 144:426 signaling, in human monocytes, PTPN22 and, 144:978 IFN-␭, production by human type 2 myeloid dendritic cells, in hepatitis C, 144:414 type I, and T-cell–mediated colitis (mice), 144:1157(correction) Interleukin(s) IL-1␤, acinar cell overexpression, and genetic models of chronic pancreatitis, 144:1080 IL-8, and colon carcinogenesis (mice), 144:155 IL-10, and production of intestinal mucus, 144:357 Intestinal secretagogues, for constipation, 144:218 –aga Intestinal transit, interactions with microbiota and diet, in humanized mice, 144:967 Intestine, normal human, expression quantitative trait loci (eQTL) analysis, 144:1328 – cov, 144: 1339 – e, 144:1488 Iron, Iron Physiology and Pathophysiology in Humans, 144:464 – pmr Iron oxides, in imaging, 144:1262 Irritable bowel syndrome bowel habits in, implications for treatment, 144:239 –ss constipation-predominant, 144:218 –aga, 144:239 –ss medical management of, 144:218 –aga diarrhea-predominant, 144:239 –ss effects of gluten-free diet in, 144: 859 – cov, 144:903 HLA associated with, 144:903 gluten sensitivity and, 144:859 – cov, 144:903 mixed pattern, 144:239 –ss treatment of, 144:239 –ss unsubtyped, 144:239 –ss J Jagged-1, upregulation in hepatocellular carcinoma, YAP and, 144: 1530 Juvenile polyposis syndrome, genetics of, 144:1402 K Kinesin motor protein, Kif 3a, and genetic models of chronic pancreatitis, 144:1080

SUBJECT INDEX

Kras and genetic models of chronic pancreatitis, 144:1080 in pancreatic tumor development and progression, 144:1220 Kupffer cells, in differential response to interferon therapy for HCV, 144:402 L Lansoprazole, microscopic colitis induced by, 144:857– ccig Laxatives osmotic, for constipation, 144:218 –aga stimulant, for chronic constipation, 144: 218 –aga Leiomyoma, pancreatic benign metastasizing, 144:659 – ccig Lemmel’s syndrome, 144:468 – ccig Lipids, malabsorption, bile acid conjugation defects and, 144:945 Liver cancer. See also Cholangiocarcinoma; Hepatocellular carcinoma Akt/mTORC1 and (mice), 144:1055 Concise Pediatric and Adolescent Hepatology, 144:465–pmr diseases of. See Liver disease failure, acute-on-chronic, 144:1337– e, 144:1426 definition of, East–West divide in, 144:1337– e, 144:1426 fibrosis. See Fibrosis, hepatic Hepatobiliary Transport in Health and Disease, 144:855–pmr injury drug-induced, 144:1328 – cov, 144: 1335– e, 144:1419 monoacylglycerol lipase and (mice), 144:808 stiffness acoustic radiation force impulse measurement of, 144:19 – e in cirrhosis, 144:2– cov, 144:19 – e, 144:102, 144:851–ss, 144: 1150 – c, 144:1151– c elastography-based assessment of, 144: 2– cov, 144:19 – e, 144:102, 144: 1150 – c, 144:1151– c and prognosis, in primary biliary cirrhosis, 144:851–ss reliability of, 144:243–ss and identification of cirrhotic patients with esophageal varices, 144:2– cov, 144:19 – e, 144:102, 144: 1150 – c, 144:1151– c transplantation. See Liver transplantation Liver disease. See also Nonalcoholic fatty liver disease bile acid conjugation defects and, 144: 945

e49

coffee and, 144:670 – ce Hepatobiliary Transport in Health and Disease, 144:855–pmr Schiff’s Diseases of the Liver, 11th Edition, 144:1567–pmr Liver transplantation and HCV, management of, 144:482– ce renal function after, everolimus and, 144: 459 –ss Liver X receptors LXR␤, deletion, and genetic models of chronic pancreatitis, 144:1080 protective effect against intestinal tumorigenesis (mice), 144:1497 Lynch-like syndrome, colorectal cancer risk in, 144:868 – e, 144:926 Lynch syndrome, without germline mutation, risk of cancer in, 144:868 – e, 144:926 M Macrophages, tumor-associated, and pancreatic cancer, 144:1230 Magnetic resonance colonography, for detection of colorectal neoplasia, 144:664 – cov, 144:684 – e, 144:743 Major histocompatibility complex, 144:1357–rev Malabsorption, claudin-2/15 loss and (mice), 144:369 Mammalian target of rapamycin (mTOR) pathway, mTORC1, in hepatic tumorigenesis (mice), 144:1055 Mast cells interactions with nerves, functions and imaging of, 144:698 –iat and pancreatic cancer, 144:1230 MedicineNet information on IBD, 144:248 –pmr patient-oriented Internet content from, 144:246 –pmr Melanin-concentrating hormone, central, and liver and adipose metabolism, 144:475– cov, 144:501– e, 144:636 Melanocortin-4 receptors, and effects of roux-en-Y gastric bypass on glucose homeostasis (mice, humans), 144:474 – cov, 144:497– e, 144:580 Melanoma, primary esophageal, 144: 856 – ccig Mentoring, Education, and Training Corner A call for investment in education of US minorities in the 21st century, 144:863

e50

SUBJECT INDEX

Direct trainee observation: Opportunities for enhanced physician–patient communication and faculty development, 144:1330 Gastroenterology and biodesign: Contributing to the future of our specialty, 144:258 Personal perspectives on mentoring, 144: 488 Physicians’ Pathways to Non-Traditional Career and Leadership Opportunities, 144:655–pmr Procedural competency of gastroenterology trainees: From apprenticeship to milestones, 144:677 The state of simulation in endoscopy education: continuing to advance toward our goals, 144:9 Mentoring, personal perspectives on, 144:488 Metabolic syndrome microbiota transfer in, and insulin sensitivity, 144:250(correction) risk reduction, celiac disease and, 144: 912 Metabolomics of hepatocellular carcinoma, 144:860 – cov, 144:1066 in humanized mice, 144:967 Metastases, in rodent models of colon cancer, 144:705–rev Microbiome, of complex cholestatic disorders, 144:1357–rev Microbiota bile acids as modulators of, 144:844 –ss cancer-inducing activity of, colitis and, 144:461–ss in inflammatory bowel disease, 144:36 – rev dietary habits and, 144:844 –ss interactions with carbon monoxide and heme oxygenase-1 (mice, zebrafish), 144:789 interactions with diet and intestinal transit, in humanized mice, 144:967 and intestinal angiogenesis, 144:613 regulation of host gene expression by, 144:841–ss stress-induced CRH-mediated NLRP6 inflammasome inhibition and (mice), 144:1478 transfer, in metabolic syndrome, and insulin sensitivity, 144:250(correction) Microbubbles, for imaging of tumor microvasculature, 144:1262 MicroRNAs correlation with HMGA1 and FMNL2 in colorectal cancer (mice), 144:624 miR-218, in pancreatic cancer, silencing by EZH2, 144:1086

GASTROENTEROLOGY Vol. 144, No. 7

Microsatellite instability, and colorectal cancer, 144:868 – e, 144: 926 Minnelide, preclinical studies, animal models for, 144:1094 miRNA. See MicroRNAs Mitomycin C, extravasation, cutaneous sclerosis caused by, 144: 1158 – ccig Molecular imaging for pancreatic ductal adenocarcinoma, 144:1262 principles, 144:1262 Monoacylglycerol lipase, and hepatic injury (mice), 144:808 MRK-003, and therapy targeted against pancreatic cancer stem cells, 144:1241 mTORC1, in hepatic tumorigenesis (mice), 144:1055 Mucin, production in goblet cells, IL-10 and, 144:357 Mucosa Biopsy Interpretation of the Gastrointestinal Tract Mucosa, Volume 2: Neoplastic, 2nd Edition, 144:1147–pmr Cell/Tissue Injury and Cytoprotection/Organoprotection in the Gastrointestinal Tract: Mechanisms, Prevention and Treatment, 144:1568 –pmr intestinal, growth of, regulation by neuronal serotonin (mice), 144: 249(correction) Mucosal barrier, IL-10 and, 144:357 Myeloid cells, immature, mobilization of, IL-8 and (mice), 144:155 Myeloid-derived suppressor cells (MDSCs), and pancreatic cancer, 144:1230 Myosin phosphatase target subunit 1, and intestinal smooth muscle contractile phenotypes (mice), 144:1456 N Narrow-band imaging, for optical biopsy of colorectal polyps, in community practice, 144:1– cov, 144:81 Natural killer T cells and clearance of hepatitis B virus (mice), 144:256 – cov, 144:392 and pancreatic cancer, 144:1230 Necrolytic acral erythema, 144: 469 – ccig Necroptosis, in gastrointestinal tract, 144:283–rev Neuron-derived orphan receptor 1 and hepatocyte proliferation, 144:1518 upregulation in liver cancer, 144:1518

Neutrophils, recruitment, and pancreatic cancer, 144:1230 Nobel Prize, awarded for studies of pancreas, 144:1166 Nod-like receptor, and intestinal angiogenesis, 144:613 Nonalcoholic fatty liver disease, coffee and, 144:670 – ce Nonalcoholic steatohepatitis (NASH) 27-hydroxycholesterol in, beneficial effects (mice), 144:167 role of CYP27A1 in (mice), 144:167 Notch signaling, in hepatocellular carcinoma, YAP and, 144:1530 Nuclear factor ␬B, and pancreatitis (mice), 144:3– cov, 144:26 – e, 144:192, 144:202, 144:1076 Nutrient transport, in gut, claudin2/15 loss and (mice), 144:369 O Obesity and exocrine pancreatic disorders, 144: 1199 and pancreatic cancer, 144:1252 and pancreatitis, 144:1252 Optical coherence microscopy, full-field, of gut neuronal elements, 144:698 –iat Optical coherence tomography, of gut neuronal elements, 144: 698 –iat Optical endomicroscopy, of pancreas, 144:1262 Osteoporosis, proton pump inhibitors and, 144:650 –ss Overweight. See Obesity Owyang, Chung, recipient of the Julius M. Friedenwald Medal, 144:1554 –aga P Pancreas biology, 144:1163 cell identity in, 144:1170 cell lineages, formation, 144:1170 cystic lesions analysis of cyst fluid, 144:1303 clinical advances in, historical perspective on, 144:1249 imaging, 144:1262 cystic neoplasms, 144:1163 branch duct intraductal papillary mucinous, 144:1303 evaluation, 144:1303 management, 144:1303 risk of malignancy, 144:1303 surveillance strategies, 144:1303 endoscopic ultrasound of, 144:1303 intraductal, 144:1249

June 2013

intraductal papillary mucinous, 144: 1303 management, 144:1303 mucinous, 144:1249, 144:1303 surgery for, 144:1303 development, control of cell identity in, 144:1170 endocrine cells differentiation and maintenance of phenotype, 144:1170 plasticity, 144:1170 exocrine development, 144:1170 injury, cellular responses to, 144:1170 plasticity, 144:1170 exocrine– endocrine interconversion, 144: 1170 function, knowledge of, historical perspective on, 144:1166 imaging, 144:1163, 144:1262 historical perspective on, 144:1249 regeneration, control of cell identity in, 144:1170 serous cystadenoma, 144:1303 solid pseudopapillary neoplasm, 144: 1303 study of, Nobel Prizes awarded for, 144: 1166 Pancreatectomy, distal, minimally invasive, 144:1316 Pancreatic acinar cells de-differentiated, 144:1170 differentiation and maintenance of phenotype, 144:1170 Hippo signaling and (mice), 144: 1329 – cov, 144:1345– e, 144: 1543 IL-1␤ overexpression, and genetic models of chronic pancreatitis, 144:1080 and susceptibility to pancreatitis, 144: 1292 Pancreatic beta cells genetic engineering of, 144:1170 plasticity, 144:1170 regeneration, 144:1170 Pancreatic cancer adjuvant therapy, 144:1316 advanced-stage, targeted therapy for, 144:1316 animal models, 144:1163, 144:1230 genetically engineered models, 144: 1094 historical perspective on, 144:1249 orthotopic xenograft models, 144:1094 relevance to human disease, 144:1094 subcutaneous xenograft models, 144: 1094 borderline resectable, 144:1316 clinical advances in, historical perspective on, 144:1249 development

SUBJECT INDEX

adaptive and innate immune cells in, 144:1230 autophagy in, 144:1199 inflammation in, 144:1199 Kras and, 144:1220 diagnosis, 144:1163 epidemiology, 144:1163, 144:1252 genetics, historical perspective on, 144: 1249 imaging, 144:1262 immunopathogenesis, 144:1230 locally advanced, 144:1316 management, 144:1316 maintenance, Kras and, 144:1220 metastatic, 144:1316 chemotherapy for, advances in, 144: 1316 microenvironment, 144:1241 Kras in, 144:1220 pancreatic stellate cells and, 144:1210 minimally invasive surgery for, 144:1316 miR-218 in, silencing by EZH2, 144: 1086 molecular imaging agents for, 144:1262 molecular mechanisms, 144:1163 mortality rate for, 144:1163, 144:1252 neoadjuvant therapy, 144:1316 obesity and, 144:1252 pancreatic stellate cells and, 144:1210 pancreatitis and, 144:1170 progression delay by ENO1 DNA vaccination (mice), 144:861– cov, 144:1098 inflammation and, 144:1170 Kras and, 144:1220 resectable, 144:1316 risk chronic pancreatitis and, 144:1252 drugs affecting, 144:1252 hereditary pancreatitis and, 144:1252 infectious diseases and, 144:1252 risk factors for, 144:1252 stem cells biology, 144:1241 clinical applications, 144:1241 markers, 144:1241 and signaling pathways, 144:1241 therapy targeted to, 144:1241 treatment, 144:1163 advances in, 144:1316 CRM-1 inhibitors in (mice), 144:257– cov, 144:447 evaluation, animal models for, 144: 1094 historical perspective on, 144:1249 immune-based, 144:1230 Kras targeting in, 144:1220 Pancreatic disorders clinical advances in, historical perspective on, 144:1249 detection, 144:1163

e51

epidemiology, 144:1163, 144:1252 genetic risk factors for, 144:1292 imaging in, 144:1262 inflammation, autophagy, and obesity in, 144:1199 knowledge of, historical perspective on, 144:1166 pathophysiology, 144:1163 risk factors for, 144:1163 treatment, cellular plasticity and, 144: 1170 Pancreatic ductal adenocarcinoma. See Pancreatic cancer Pancreatic duct cells differentiation and maintenance of phenotype, 144:1170 dysfunction, and pancreatitis, 144:1292 Pancreatic endocrine neoplasms, cystic, 144:1303 Pancreatic enzyme(s), commercial preparations, 144:1282 Pancreatic necrosis, infected, conservative treatment of, 144: 333, 144:1574 – c Pancreaticoduodenectomy, minimally invasive, 144:1316 Pancreatitis acute, 144:1163 adaptive and innate immune cells in, 144:1230 age distribution, 144:1252 analgesia for, 144:1272 animal models, 144:1180, 144:1230 duct obstruction and bile acid infusion, 144:1180 relevance to human disease, 144: 1094 secretagogue hyperstimulation, 144: 1180 clinical management, 144:1272 definition, 144:1272 diagnosis, 144:1272 drug-induced, 144:1252, 144:1272 ductal disruption in, 144:1272 early fluid resuscitation for, 144:1272 epidemiology, 144:1252 extrapancreatic complications, management, 144:1272 and hypercalcemia, 144:1272 hypertriglyceridemic, 144:1272 idiopathic recurrent, endoscopic treatment of, 144:1570 – c, 144: 1571– c I␬B␣ in (mice), 144:3– cov, 144: 26 – e, 144:192 imaging, 144:1272 immune-mediated, animal models, 144:1180 incidence, 144:1252 infectious, animal models, 144:1180

e52

SUBJECT INDEX

initial resuscitation and management for, 144:1272 intensive care for, indications for, 144: 1272 local complications definition, 144:1272 management, 144:1272 mortality rate for, 144:1252 necrosis in, 144:1272 nutritional support in, 144:1272 organ failure in, definition, 144:1272 outpatient management, 144:1272 peripancreatic vascular complications in, 144:1272 prevalence, 144:1252 prevention, 144:1272 prognostic factors for, 144:1272 progression, 144:1252, 144:1292 prophylactic antibiotics in, 144:1272 pseudocyst in, 144:1272 revised Atlanta classification, 144: 1272 risk factors for, 144:1272 severity, definition, 144:1272 sex distribution, 144:1252 susceptibility to, 144:1292 systemic complications, definition, 144:1272 transfer of patient with, indications for, 144:1272 treatment, 144:1272 health care disparities and, 144: 1272 health care reform and, 144:1272 quality improvement, 144:1272 trends in, 144:1252 acute recurrent alcohol and, 144:1292 duodenal duplication cyst and pancreas divisum as concomitant causes of, 144:1158 – ccig progression to chronic pancreatitis, 144:1292 susceptibility to, 144:1292 alcohol and, 144:1252, 144:1292 alcoholic CLDN2 locus and, 144:1292 mitochondrial transition pore and (mice), 144:265– e, 144:437 necrosis in (mice), 144:265– e, 144: 437 and progression, 144:1292 anatomic abnormalities and, 144:1252 animal models, 144:1163, 144:1180, 144:1230 biologic factors and, 144:1180 chemical factors and, 144:1180 environmental factors and, 144:1180 ethanol feeding and, 144:1180 relevance to human disease, 144:1094 arginine model, 144:1094

GASTROENTEROLOGY Vol. 144, No. 7

autoimmune. See Autoimmune pancreatitis autoimmune disease and, 144:1252 basic amino acid–induced, animal models, 144:1180 biliary, ERCP for, timing of, 144:1272 and cancer, 144:1170 cerulein-induced, 144:1076, 144:1094, 144:1180 and cholangitis, associated with juxtapapillary diverticulum, 144:468 – ccig chronic, 144:1163 adaptive and innate immune cells in, 144:1230 age distribution, 144:1252 animal models, 144:1180, 144:1230 cerulein-induced (mice), 144:1076, 144:1180 clinical advances in, historical perspective on, 144:1249 diagnosis, 144:1282 endocrine insufficiency in, management, 144:1282 endoscopic ultrasound in, 144:1262 epidemiology, 144:1252 etiology, determination of, 144:1282 exocrine insufficiency in, management, 144:1282 genetic medicine and, 144:1249 genetics, 144:1292 imaging, 144:1282 incidence, 144:1252 management, 144:1282 mortality rate for, 144:1252 pain management for, 144:1282 and pancreatic cancer risk, 144:1252 prevalence, 144:1252 sex distribution, 144:1252 treatment, 144:1282 trends in, 144:1252 diabetes and, 144:1252, 144:1282 diet and, 144:1252 diet-induced, 144:1094 animal models, 144:1180 duct cell dysfunction and, 144:1292 duct infusion model, 144:1094 duct obstruction and, 144:1252 duct obstruction model, 144:1094 epidemiology, 144:1252 gallstones and, 144:1252 genetic models, 144:1180 genetics, 144:1292 hereditary, 144:1163 and pancreatic cancer risk, 144:1252 hypertriglyceridemic, 144:1252, 144: 1272 immune, animal models, 144:1180 impaired autophagy in, 144:1199 infectious, animal models, 144:1180 inflammation in, 144:1199

lifestyle factors and, 144:1252 mechanical models, 144:1180 metabolic factors and, 144:1252 molecular mechanisms, 144:1163 nuclear factor-␬B in (mice), 144:3– cov, 144:26 – e, 144:192, 144:202 obesity and, 144:1252 post-ERCP, prevention, 144:1272 progression, 144:1252, 144:1292 racial distribution, 144:1252 risk, duct biology and, 144:1292 risk factors for, 144:1252 smoking and, 144:1252 treatment, immune-based, 144:1230 Pancreatoscopy, 144:1262 Paraneoplastic syndrome, pseudoachalasia in, 144:252– ccig Pathology Biopsy Interpretation of the Gastrointestinal Tract Mucosa, Volume 2: Neoplastic, 2nd Edition, 144:1147–pmr mouse, nomenclature for, 144:705–rev of rodent models of intestinal cancer, 144:705–rev PBC. See Primary biliary cirrhosis Pediatrics, Concise Pediatric and Adolescent Hepatology, 144: 465–pmr Pelvic floor dysfunction, management of, 144:218 –aga Peptic ulcer disease, aspirin-related bleeding in, Helicobacter pylori and, 144:528 Periostin, optical imaging of, and early endoscopic detection of esophageal cancer (mice), 144:294 Peristalsis, bile acid– evoked, TGR5 receptor and (mice), 144:145 Peutz-Jeghers syndrome, 144:1402 Physiology, Physiology of the Gastrointestinal Tract, 5th edition, 144:1569 –pmr Platelet-derived growth factor receptor, Pdgfr␣, and GIST-like tumor formation (mice), 144: 134 Polycystic kidney disease, autosomal recessive, congenital hepatic fibrosis in, 144:112, 144:1155– c Polyp(s), colorectal germline mutations and, 144:1402 hyperplastic, pathological reassessment of, 144:1564 –ss narrow band imaging of, in community practice, 144:1– cov, 144:81 optical biopsy of, by narrow band imaging, in community practice, 144: 1– cov, 144:81

June 2013

serrated, misclassification of, 144: 1564 –ss sessile, endoscopic resection of, 144:30 –v surveillance, 144:1564 –ss Polypectomy colonoscopic technique for, 144:16 – e, 144:74 incomplete and interval cancers, 144:16 – e, 144:74 rates of, 144:16 – e, 144:74 retroflexion in colonoscopy for, 144: 883–v Polyposis syndromes cancer risks for, 144:1402 germline mutations in, 144:1402 incidence of, 144:1402 Portal hypertension in HCV-related cirrhosis, evaluation by measurement of spleen stiffness, 144:1152– c noninvasive predictors of, 144:1150 – c in patients with compensated cirrhosis, identification of, 144:2– cov, 144: 19 – e, 144:102, 144:1150 – c, 144:1151– c Portal vein, thrombosis, in cirrhosis, anticoagulation for, 144: 848 –ss Portal venous gas, hydrogen peroxide ingestion causing, 144: 658 – ccig Pregnancy, fetal growth and outcomes in, gluten intolerance and, 144:726 Primary biliary cirrhosis animal models of, 144:1357–rev clinical phenotype of, sex and age and, 144:474 – cov, 144:494 – e, 144: 560 elastography-based assessment of fibrosis in, and prognosis, 144:851–ss follow-up for, 144:474 – cov, 144:494 – e, 144:560 genetics of, 144:1357–rev Hepatobiliary Transport in Health and Disease, 144:855–pmr non-HLA associations in, 144:1357–rev response to ursodeoxycholic acid, factors affecting, 144:474 – cov, 144: 494 – e, 144:560 Primary sclerosing cholangitis animal models of, 144:1357–rev genetics of, 144:1357–rev Hepatobiliary Transport in Health and Disease, 144:855–pmr non-HLA associations in, 144:1357–rev Print and Digital Media Reviews Atlas of Gastrointestinal Endomicroscopy, 144:854

SUBJECT INDEX

Autoimmune Hepatitis: A Guide for Practicing Clinicians, 144:54 Biopsy Interpretation of the Gastrointestinal Tract Mucosa, Volume 2: Neoplastic, 2nd Edition, 144:1147 Cell/Tissue Injury and Cytoprotection/Organoprotection in the Gastrointestinal Tract: Mechanisms, Prevention and Treatment, 144:1568 Concise Pediatric and Adolescent Hepatology, 144:465 The Esophagus, 5th Edition, 144:1148 Essentials of Gastroenterology, 144:853 Gastroparesis: Pathophysiology, Presentation and Treatment, 144:1146 Hepatobiliary Transport in Health and Disease, 144:855 Iron Physiology and Pathophysiology in Humans, 144:464 Physicians’ Pathways to Non-Traditional Career and Leadership Opportunities, 144:655 Physiology of the Gastrointestinal Tract, 5th edition, 144:1569 Practical Fluoroscopy of the GI and GU Tracts, 144:656 Schiff’s Diseases of the Liver, 11th Edition, 144:1567 Self-Expanding Stents in Gastrointestinal Endoscopy, 144:245 update on, 144:486 – ce Washington Manual® Subspecialty Consult Series in Gastroenterology, 3rd Edition, 144:466 Protein kinase-like ER kinase (PERK), RNA-dependent, and genetic models of chronic pancreatitis, 144:1080 Protein tyrosine phosphatase nonreceptor type 22, and IFN-␥–induced signaling, in intestinal inflammation, 144: 978 Proton pump inhibitors, and bone mineral density, 144:650 –ss PSC. See Primary sclerosing cholangitis Pseudoachalasia, in paraneoplastic syndrome, 144:252– ccig PTEN, mutations, and colorectal polyps, 144:1402 Publication, top 100 clinical articles in digestive disease, bibliometrics of, 144:673– ce Q Quality of care for acute pancreatitis, 144:1272 for liver transplant patients with HCV, 144:482– ce

e53

for patients with cirrhosis and HCV, 144:482– ce for patients with HCV and medical comorbidities, 144:482– ce for patients with HIV and HVC, 144: 482– ce Quercetin, and therapy targeted against pancreatic cancer stem cells, 144:1241 R Rectal cancer. See also Colorectal cancer early, with Pagetoid spread, 144:1160 – ccig Reflux esophagitis, polygenic traits, 144:667– ce Reviews in Basic and Clinical Gastroenterology and Hepatology Brain-gut interactions in inflammatory bowel disease, 144:36 Complex roles of caspases in the pathogenesis of inflammatory bowel disease, 144:283 The genetics of complex cholestatic disorders, 144:1357 Hepatocellular benign tumors—From molecular classification to personalized clinical care, 144:888 Pathology of rodent models of intestinal cancer: Progress report and recommendations, 144:705 Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma, 144: 512 Right Diagnosis, patient-oriented Internet content from, 144: 246 –pmr Rituximab, for relapsing autoimmune pancreatitis, 144:1144 –ss RNA (ribonucleic acid) long noncoding, AFAP1-AS1, overexpression in Barrett’s esophagus and esophageal adenocarcinoma, 144:956 noncoding. See also MicroRNAs dysregulation in Barrett’s esophagus and esophageal adenocarcinoma, 144:956 Roux-en-Y gastric bypass, effects on glucose homeostasis (mice, humans), 144:474 – cov, 144: 497– e, 144:580 Rustgi, Anil K., 144:1129 –aga S Sacral nerve stimulation, for constipation, 144:218 –aga

e54

SUBJECT INDEX

SB431542, and therapy targeted against pancreatic cancer stem cells, 144:1241 Selected Summaries Anticoagulant therapy for portal vein thrombosis in liver: Is it worth a buy?, 144:848 Bile acids as modulators of gut microbiota linking dietary habits and inflammatory bowel disease: A potentially dangerous liaison, 144:844 Colitis, microbiota, and colon cancer: An infernal triangle, 144:461 The cost-effectiveness of birth cohort screening for hepatitis C antibody in US primary care settings, 144: 457 Everolimus for liver transplant recipients: Is it ready for prime time?, 144: 459 The final word on proton pump inhibitors and osteoporosis?, 144:650 First-line eradication therapy for Helicobacter pylori: Time for a change?, 144:652 How common are lymph node metastases in patients with Barrett’s esophagus complicated by high-grade dysplasia or intramucosal cancer?, 144:242 IBS bowel habits and associated symptoms: Forming a clearer picture, 144:239 Liver stiffness measurement: Simplicity is a prerequisite for reliability, 144: 243 Management of severe sterid-refractory ulcerative colitis: cyclosporine or infliximab?, 144:1138 A new treatment algorithm for relapsing autoimmune pancreatitis?, 144: 1144 Platelet plays a role in the pathogenesis of hepatitis B virus–related hepatocellular carcinoma, 144:1140 Predicting clinical outcomes with elastography in primary biliary cirrhosis: One step closer?, 144:851 Proinflammatory wheat attacks on the intestine: Alpha-amylase trypsin inhibitors as new players, 144: 1561 Regulation of host gene expression by gut microbiota, 144:841 Serrated polyps misclassified: The value of looking back and the impact of looking forward, 144:1564 A tailored vs empiric diet—Which is best for eosiniphilic esophagitis?, 144:1560

GASTROENTEROLOGY Vol. 144, No. 7

Tertiary prevention of hepatitis B-related hepatocellular carcinoma, 144: 1142–ss Tofacitinib: Janus bifrons in ulcerative colitis treatment, 144:1136 Ustekinumab for moderate-to-severe Crohn’s disease, 144:846 Selective inhibitors of nuclear export, in pancreatic cancer treatment (mice), 144:257– cov, 144:447 Serotonin, neuronal, regulation of intestinal epithelial homeostasis (mice), 144:249(correction) Serotonin receptor antagonists, 5-HT4 , for constipation, 144: 218 –aga Serous cystadenoma, pancreatic, 144:1303 Serpins, SERPINA3, antitumoral role in liver (mice), 144:818 Simeprevir, for hepatitis C, 144: 482– ce Single nucleotide polymorphisms (SNP), CRC-associated, 144: 665– cov, 144:799 and adenoma predisposition, 144:53 Sleeping Beauty transposon system, in mouse model, 144: 705–rev SMAD4, mutations, and colorectal polyps, 144:1402 Smoking, and pancreatitis, 144:1252 Smooth muscle, intestinal, contractile phenotypes in MYPT1 knockout mice, 144:1456 Sodium, paracellular flow in gut, claudin-2/15 loss and (mice), 144: 369 Sofosbuvir, for hepatitis C, 144: 482– ce Sonic Hedgehog, overexpression, and genetic models of chronic pancreatitis, 144:1080 SPDEF, tumor-suppressor functions in colorectal cancer, 144:1012 Sphincter of Oddi. See also Sphincterotomy dysfunction, opiates and, 144:1571– c Sphincter of Oddi manometry, in acute idiopathic recurrent pancreatitis, 144:1570 – c, 144: 1571– c Sphincterotomy in acute idiopathic recurrent pancreatitis, 144:1570 – c, 144:1571– c endoscopic, with balloon dilatation, vs endoscopic sphincterotomy alone, for removal bile duct stones, 144: 341

Spleen, stiffness and identification of cirrhotic patients with esophageal varices, 144:2– cov, 144:19 – e, 144:92, 144: 1151– c, 144:1152– c measurement of by acoustic radiation force impulse imaging, 144:2– cov, 144:19 – e, 144:92, 144:1151– c, 144: 1152– c in HCV-related cirrhosis, 144:1152– c by transient elastography, 144:19 – e Splenosis, posttraumatic, 144:659 – ccig Statins effects on carcinogenesis, 144:255– cov, 144:323, 144:1572– c risk modification of hepatocellular carcinoma with, 144:255– cov, 144: 323, 144:1572– c Steatohepatitis, reduction by 27hydroxycholesterol (mice), 144:167 Stellate cells, pancreatic and pancreatic cancer, 144:1230 and pancreatic cancer microenvironment, 144:1210 Stem cell markers in pancreatic cancer, 144:1241 in rodent models of colon cancer, 144: 705–rev Stem cells adult, slowly cycling, in esophagus and stomach, 144:761 cancer biology, 144:1241 in hepatocellular carcinoma, ICAM-1 expression by, 144:1031 in pancreatic cancer biology, 144:1241 clinical applications, 144:1241 markers, 144:1241 and signaling pathways, 144:1241 therapy targeted to, 144:1241 Lgr5⫹ regulation by Foxf2, 144:873– e, 144: 1001 Wnt pathway in, inhibition by Troy, 144:381 Stents/Stenting, Self-Expanding Stents in Gastrointestinal Endoscopy, 144:245–pmr STK11, mutations, and colorectal polyps, 144:1402 Stomach adult stem cells in, 144:761 cancer. See Gastric cancer endoscopic submucosal dissection, novel submucosal gel for, 144:505 wall thickening, hydrogen peroxide ingestion causing, 144:658 – ccig

June 2013

Stress CRH-mediated NLRP6 inflammasome inhibition induced by, and enteritis (mice), 144:1478 gastrointestinal effects of, 144:36 –rev and inflammatory bowel disease, 144: 36 –rev Systemic lupus erythematosus, and pancreatitis, 144:1252 T T cells. See T lymphocytes (T cells) Technology, innovative, 144:258 clinical value of, evaluation, 144:5– ce Tissue transglutaminase, antibodies against, in pregnant women, and fetal weight/birth weight, 144:726 T lymphocytes (T cells). See also Natural killer T cells CD4⫹, response to Helicobacter pylori, and reduced risk of gastric disease, 144:591 CD8⫹ HCV-specific, antiviral efficacy of, ex vivo, 144:426 human intestinal, TGF-␤ signaling and, 144:601 and pancreatic cancer, 144:1230 helper, and pancreatic cancer, 144:1230 regulatory Foxp3 expression, IFN and, in colitis (mice), 144:1157(correction) and pancreatic cancer, 144:1230 Tobacco. See Smoking Tofacitinib, for ulcerative colitis, 144: 1136 –ss Toll-like receptor, and intestinal angiogenesis, 144:613 Training, in gastroenterology. See Education and training; Mentoring, Education, and Training Corner Transforming growth factor, TGF-␤ signaling and human intestinal CD8⫹ T suppressor cell activity, 144:601 promotion of hepatic fibrosis and carcinogenesis in TK1 knockout mice, 144:1042 TGF-␤1, and genetic models of chronic pancreatitis, 144:1080

SUBJECT INDEX

Transforming growth factor-␤activated kinase (TAK1), in hepatocytes, inactivation of, and hepatic fibrosis and carcinogenesis, 144:1042 Triggering receptor expressed on myeloid cells-2 (TREM-2), in pathogenesis of of IBD, 144:346 Troy, and Wnt signaling in intestinal stem cells, 144:381 Trypsin activation, and pancreatitis progression, 144:1292 and cerulein-induced chronic pancreatitis in mice, 144:1076 Tumorigenesis hepatic Akt in, 144:1055 mTORC1 in (mice), 144:1055 intestinal, protective effect of liver X receptors against (mice), 144:1497 Tumor necrosis factor, TNF␣, antibodies. See Infliximab; Ustekinumab U Ulcerative colitis. See also Inflammatory bowel disease mouse model, alleviation by molecular/ chemical chaperones, 144:989 polygenic traits, 144:667– ce severe steroid-refractory, cyclosporine vs infliximab for, 144:1138 –ss tofacitinib for, 144:1136 –ss work days lost in, presurgery and postcolectomy, 144:536 Ultrasound, intraductal, of pancreas, 144:1262 UpToDate, information on IBD, 144: 248 –pmr Ursodeoxycholic acid, for primary biliary cirrhosis, response to, factors affecting, 144:474 – cov, 144:494 – e, 144:560 Ustekinumab, for Crohn’s disease, 144:846 –ss V Vagal nerve stimulation, for gastrointestinal inflammation, 144: 36 –rev Vertical sleeve gastrectomy, ghrelin-independent effects of (mice), 144:50

e55

Visceral hypersensitivity, developmental origins of (rats), 144:570 Vitamins, fat-soluble, deficiency of, bile acid conjugation defects and, 144:945 W WebMD information on IBD, 144:248 –pmr patient-oriented Internet content from, 144:246 –pmr Website review On inflammatory bowel disease found on websites WebMD, eMedicineHealth, MedicineNet, Crohn’s and Colitis Foundation of America, Foundation for Clinical Research in IBD, UpToDate, and Wikipedia, 144:248 On patient-oriented Internet content on celiac sprue found on websites of Celiac Sprue Association, eMedicineHealth, MedicineNet, Celiac.com, WebMD, Right Diagnosis, and Celiac Disease Foundation, 144:246 Wheat, amylase trypsin inhibitors, and intestinal inflammation, 144: 1561–ss Wikipedia, information on IBD, 144: 248 –pmr Wistar Bonn/Kobori rats, and genetic models of chronic pancreatitis, 144:1080 Wnt signaling intestinal, inhibition by Foxf2, 144: 873– e, 144:1001 in intestinal stem cells, inhibition by Troy, 144:381 X XL184, and therapy targeted against pancreatic cancer stem cells, 144:1241 Y Yes-associated protein (YAP), and Notch signaling in hepatocellular carcinoma, 144:1530 Z ZBP-89, regulation of enterochromaffin cell tryptophan hydroxylase 1 (Tph1) gene, 144:1466 Zinc finger transcription factor, ZBP-89, regulation of enterochromaffin cell tryptophan hydroxylase 1 (Tph1) gene, 144:1466